Skip header and navigation

Refine By

184 records – page 1 of 19.

The absorption of subcutaneously injected short-acting soluble insulin: influence of injection technique and concentration.

https://arctichealth.org/en/permalink/ahliterature48905
Source
Diabetes Care. 1983 Sep-Oct;6(5):459-62
Publication Type
Article
Author
P. Hildebrandt
L. Sestoft
S L Nielsen
Author Affiliation
Hvidøre Hospital, Klampenborg, Denmark.
Source
Diabetes Care. 1983 Sep-Oct;6(5):459-62
Language
English
Publication Type
Article
Keywords
Absorption
Adolescent
Adult
Diabetes Mellitus, Type 1 - drug therapy - metabolism
Humans
Injections, Subcutaneous - methods
Insulin - administration & dosage - pharmacokinetics
Middle Aged
Temperature
Abstract
The effect of injection technique on the absorption of subcutaneously injected short-acting insulin [125I-labeled Actrapid (MC), Novo, Copenhagen, Denmark] was investigated in insulin-dependent diabetic patients. In one side of the abdomen insulin was given with a fixed standard technique. In the other side of the abdomen the temperature of the injected insulin, the depth of injection, and the duration of injection were varied. Furthermore, we compared the absorption of U40 and U100 insulin by giving either 8 U of the two insulins or 0.1 ml of both insulins simultaneously to the patients in either side of the abdomen. With regard to the injection technique the only significant finding was a faster absorption rate with deep (12 mm) than with superficial (3 mm) injection. The absorption of U100 insulin was significantly slower than of U40 insulin, when given in the same amount (8 U) as well as in the same volume (0.1 ml).
PubMed ID
6400706 View in PubMed
Less detail

[Acute non ST-elevation coronary syndrome in real practice of hospitals in Russia. Comparative data from RECORD 2 and RECORD registries].

https://arctichealth.org/en/permalink/ahliterature119478
Source
Kardiologiia. 2012;52(10):9-16
Publication Type
Article
Date
2012
Author
A D Erlikh
N A Gratsianskii
Source
Kardiologiia. 2012;52(10):9-16
Date
2012
Language
Russian
Publication Type
Article
Keywords
Acute Coronary Syndrome - diagnosis - epidemiology - therapy
Adult
Aged
Aged, 80 and over
Anticoagulants - administration & dosage
Coronary Angiography
Electrocardiography
Female
Follow-Up Studies
Heparin, Low-Molecular-Weight - administration & dosage
Hospital Mortality - trends
Hospitals - statistics & numerical data
Humans
Incidence
Injections, Subcutaneous
Male
Middle Aged
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors - administration & dosage
Registries
Retrospective Studies
Russia - epidemiology
Survival Rate - trends
Ticlopidine - administration & dosage - analogs & derivatives
Treatment Outcome
Young Adult
Abstract
to compare data on pre- and in hospital treatment of non ST-elevation (NSTE) acute coronary syndromes (ACS) in Russian ACS registers RECORD (recruitment from 11.2007 to 02.2008) and RECORD-2 (from 04/2009 to 04.2011).
Four of 7 hospitals participating in RECORD-2 were invasive (57.1% vs. 55.6% in RECORD). In RECORD-2 10-30 consecutive patients with NSTEACS were included monthly in each center; recruitment in RECORD was described elsewhere.
Mean age of patients was similar in two registries. Portion of women was significantly higher in RECORD-2 (42.9% vs. 26.0% in RECORD; 140) gave results close to those in all patients except mortality which was statistically similar but numerically higher in RECORD-2 (9.3 vs. 7.9% in RECORD; p=0.68).
Comparison of data of 2 limited NSTEACS registers conducted with interval of about 2 years showed only modest shift towards fulfillment of contemporary recommendations which was not associated with increase in rates of PCI and improvement of outcomes especially in high risk patients.
PubMed ID
23098345 View in PubMed
Less detail

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.

https://arctichealth.org/en/permalink/ahliterature164616
Source
J Dermatolog Treat. 2007;18(1):25-31
Publication Type
Article
Date
2007
Author
Richard Shikiar
Michael Heffernan
Richard G Langley
Mary K Willian
Martin M Okun
Dennis A Revicki
Author Affiliation
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Source
J Dermatolog Treat. 2007;18(1):25-31
Date
2007
Language
English
Publication Type
Article
Keywords
Adult
Aged
Anti-Inflammatory Agents - administration & dosage - therapeutic use
Antibodies, Monoclonal - administration & dosage - therapeutic use
Antibodies, Monoclonal, Humanized
Canada
Dermatologic Agents - administration & dosage - therapeutic use
Double-Blind Method
Female
Health status
Humans
Injections, Subcutaneous
Male
Middle Aged
Psoriasis - drug therapy
Quality of Life
Questionnaires
Treatment Outcome
United States
Abstract
Psoriasis substantially impairs the health-related quality of life (HRQOL) of patients, and a comprehensive evaluation of treatment includes HRQOL measures.
To assess the impact of adalimumab on patient-reported outcomes (PROs) of patients with moderate to severe psoriasis.
In a Phase II, randomized, controlled trial, the efficacy and safety of two dosages of adalimumab (40 mg weekly or every other week) versus placebo were assessed for 12 weeks in the treatment of moderate to severe plaque psoriasis. Patients completed the Dermatology Life Quality Index (DLQI), Short-Form 36 (SF-36) Health Survey, and EuroQOL-5D (EQ-5D) at baseline and 12 weeks. The primary endpoint was the percentage of patients achieving a > or =75% reduction in the Psoriasis Area and Severity Index score (PASI 75). Investigators assessed PASI and Physician's Global Assessment (PGA) scores.
Adalimumab patients (either dosage) displayed significantly greater improvements versus placebo patients in DLQI, EQ-5D, and SF-36 Mental Component Summary scores, as well as in Bodily Pain, Vitality, Social Functioning, Role-Emotional, and Mental Health domains. The adalimumab 40-mg weekly group also reported significantly greater improvements in SF-36 Physical Component Summary scores versus the placebo group.
Both adalimumab dosages were efficacious in improving dermatology-specific and general PROs in patients with moderate to severe psoriasis.
Notes
Comment In: J Dermatolog Treat. 2007;18(1):417365258
PubMed ID
17365264 View in PubMed
Less detail

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.

https://arctichealth.org/en/permalink/ahliterature140933
Source
Osteoporos Int. 2011 Jun;22(6):1725-35
Publication Type
Article
Date
Jun-2011
Author
D L Kendler
M R McClung
N. Freemantle
M. Lillestol
A H Moffett
J. Borenstein
S. Satram-Hoang
Y-C Yang
P. Kaur
D. Macarios
S. Siddhanti
Author Affiliation
University of British Columbia, 600-1285 West Broadway, V6H 3X8 Vancouver, BC, Canada. kendler@ca.inter.net
Source
Osteoporos Int. 2011 Jun;22(6):1725-35
Date
Jun-2011
Language
English
Publication Type
Article
Keywords
Administration, Oral
Aged
Alendronate - administration & dosage - adverse effects - therapeutic use
Antibodies, Monoclonal - administration & dosage - adverse effects - therapeutic use
Antibodies, Monoclonal, Humanized
Bone Density - drug effects
Bone Density Conservation Agents - administration & dosage - adverse effects - therapeutic use
British Columbia
Epidemiologic Methods
Female
Humans
Injections, Subcutaneous
Medication Adherence - statistics & numerical data
Middle Aged
Osteoporosis, Postmenopausal - drug therapy - physiopathology - psychology
Patient Preference - statistics & numerical data
Patient Satisfaction - statistics & numerical data
Treatment Outcome
Abstract
In this study, 250 women with osteoporosis were randomized to 12 months with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly, then crossed over to the other treatment. The primary endpoint, treatment adherence at 12 months, was 76.6% for alendronate and 87.3% for denosumab.
The purpose of this study is to evaluate treatment adherence with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly.
In this multicenter, randomized, open-label, 2-year, crossover study, 250 postmenopausal women with low bone mineral density received denosumab or alendronate for 12 months, then the other treatment for 12 months. The alendronate bottle had a medication event monitoring system cap to monitor administration dates. Definitions were as follows: compliance, receiving both denosumab doses 6 (± 1) months apart or 80-100% of alendronate doses; persistence, receiving both denosumab doses and completing the month 12 visit within the visit window or = 2 alendronate doses in the final month; adherence, achieving both compliance and persistence. This report includes data from the first 12 months.
The primary study endpoint, adherence in the first 12 months, was 76.6% (95/124) for alendronate and 87.3% (110/126) for denosumab. Risk ratios for denosumab compared with alendronate at 12 months were 0.58 (p = 0.043) for non-adherence, 0.48 (p = 0.014) for non-compliance, and 0.54 (p = 0.049) for non-persistence. Subject ratings for treatment necessity, preference, and satisfaction were significantly greater for denosumab and ratings for treatment bother were significantly greater for alendronate. Adverse events were reported by 64.1% of alendronate-treated subjects and 72.0% of denosumab-treated subjects (p = 0.403). The most common adverse events were arthralgia, back pain, pain in extremity, cough, and headache (each in
PubMed ID
20827547 View in PubMed
Less detail

ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84).

https://arctichealth.org/en/permalink/ahliterature71301
Source
Drugs R D. 2003;4(4):231-5
Publication Type
Article
Date
2003
Author Affiliation
Adis International Ltd.
Source
Drugs R D. 2003;4(4):231-5
Date
2003
Language
English
Publication Type
Article
Keywords
Bone Density - drug effects
Clinical Trials, Phase II
Drug Industry
Female
Humans
Injections, Subcutaneous
Middle Aged
Multicenter Studies
Osteoporosis, Postmenopausal - drug therapy - prevention & control
Parathyroid Hormone - administration & dosage - adverse effects - therapeutic use
Randomized Controlled Trials
Recombinant Proteins - administration & dosage - adverse effects - therapeutic use
Treatment Outcome
Abstract
ALX 111 [parathyroid hormone (1-84) - NPS Allelix, recombinant human parathyroid hormone, rhPTH (1-84), PREOS] is a full-length, recombinant human parathyroid hormone. It has potential as an anti-osteoporotic agent, due to its properties as a bone formation stimulant.This profile has been selected from R&D Insight, a pharmaceutical intelligence database produced by Adis International Ltd. It has been recommended that ALX 111 should be given for 1 to 2 years and may be given in combination with an antiresorptive agent, such as estrogen or a bisphosphonate. In December 1999, Allelix Biopharmaceuticals merged with NPS Pharmaceuticals. This combined company is operating as NPS Pharmaceuticals in the US and as NPS Allelix in Canada. The merger has enabled a phase III study of ALX 111 to begin in the US, Europe and South America. NPS harmaceuticals has signed an agreement with Bio-Imaging Technologies, which will provide all image handling and analysis for this trial. Until 1994, Allelix Biopharmaceuticals and Glaxo in Canada were involved in a joint venture to investigate the efficacy of ALX 111 in osteoporosis. Allelix was subsequently, until September 1998, collaborating with Astra of Sweden in developing ALX 111. Astra had acquired exclusive worldwide rights to ALX 111 and was responsible for development of the agent. However, Astra returned all rights to ALX 111 to Allelix as a result of its merger with Zeneca to form AstraZeneca. In December 1999, Allelix Biopharmaceuticals merged with NPS Pharmaceuticals. This combined company is operating as NPS Pharmaceuticals in the US and as NPS Allelix in Canada. The merger has enabled a phase III study of ALX 111 to begin in the US, Europe and South America. The phase III trial of ALX 111 for the treatment of osteoporosis has completed patient enrolment, and phase II trials have been completed in Canada and the Netherlands. The 18-month, phase III, multicentre, placebo-controlled trial (Treatment of Osteoporosis with Parathyroid Hormone; TOP) has been designed to assess the bone-building and fracture-reducing potential of the drug, and over 2600 postmenopausal women with osteoporosis who have not received previous drug therapy for osteoporosis have been enrolled. Treatment will be completed in September 2003, but more than 75% of patients enrolled in the TOP study have chosen to enrol in an Open Label Extension Study (OLES), which allows for a total treatment period of up to 24 months. NPS Pharmaceuticals has signed an agreement with Bio-Imaging Technologies, which will provide all image handling and analysis for this trial. In September 2002, NPS Pharmaceuticals announced that it has met its patient enrolment target (n > 150) for its POWER (PTH for Osteoporotic Women on Estrogen Replacement) study; a 24-month phase III trial initiated in Europe in November 2001. In this trial, women with osteoporosis receive SC injections of ALX 111 or placebo, in combination with their existing hormone replacement therapies, to test the bone building potential of the drug. In addition to the POWER study, a clinical trial sponsored by the National Institutes of Health (NIH) is being conducted to evaluate the potential of ALX 111 to build bone in combination with another osteoporosis medication. The 'PaTH' study (PTH/alendronate) is designed to assess the effect of various combinations and sequential uses of ALX 111 and Merck's Fosamax, a drug for slowing the loss of bone due to osteoporosis. The PaTH study, initiated in May 2000 and scheduled to conclude in September 2003, involved 238 patients with postmenopausal osteoporosis. It is thought that alendronic acid and ALX 111, when administered in combination, may act in an additive manner to treat osteoporosis because they act in different ways; alendronic acid acts to inhibit resorption and ALX 111 speeds up bone formation and resorption, with a net increase in formation. Results of this study are still being analysed but preliminary results appear to be positive. The effect of ALX 111 on bone cell cultures underare still being analysed but preliminary results appear to be positive. The effect of ALX 111 on bone cell cultures under conditions of microgravity was tested in orbit on the Space Shuttle Columbia, which was launched on 16 January 2003 but did not survive re-entry. This study was one in a series of studies known as 'OSTEO' and had been prepared by researchers from NPS Pharmaceuticals using Millenium Biologix' OSTEO Mini-Lab System. Under space flight conditions, astronauts experience a loss in bone density at a rate up to ten times faster than that of earth-bound patients with osteoporosis, and it was hoped that this study would indicate the mechanism of action of ALX 111 at cellular and genetic levels. The results of these studies were represented by the samples of human bone cells, which were lost during the re-entry tragedy.
PubMed ID
12848587 View in PubMed
Less detail

Antibody stimulation in individuals without demonstrable poliovirus antibodies following a fifth injection of inactivated poliovirus vaccine.

https://arctichealth.org/en/permalink/ahliterature13374
Source
Acta Pathol Microbiol Scand [B] Microbiol Immunol. 1973 Dec;81(6):795-8
Publication Type
Article
Date
Dec-1973

Antigen-induced changes in the endocrine function of the thymus in CBA mice during aging: role of peptide factors released by the pineal gland.

https://arctichealth.org/en/permalink/ahliterature57366
Source
Bull Exp Biol Med. 2005 Jun;139(6):724-6
Publication Type
Article
Date
Jun-2005
Author
I F Labunets
Author Affiliation
Institute of Gerontology, Academy of Medical Sciences of Ukraine, Kiev, Moscow. admin@geront.kiev.ua
Source
Bull Exp Biol Med. 2005 Jun;139(6):724-6
Date
Jun-2005
Language
English
Publication Type
Article
Keywords
Aging - immunology
Animals
Antigens - immunology
Erythrocytes - immunology
Female
Immunization
Injections, Intraperitoneal
Injections, Subcutaneous
Mice
Mice, Inbred CBA
Oligopeptides - immunology - pharmacology
Peptides - immunology - pharmacology
Pineal Gland - immunology - physiology
Sheep
T-Lymphocytes - immunology
Thymic Factor, Circulating - immunology
Thymus Gland - immunology
Thymus Hormones - blood - immunology
Time Factors
Abstract
The titer of thymic serum factor was measured in adult and old CBA females 15, 30, and 60 min, 24, 48, 72, and 96 h after injection of 3% suspension of sheep erythrocytes and changes of this parameter under the effect of epithalamin were studied in old immunized mice. The titer of thymic serum factor increased appreciably in adult mice virtually at all periods of the study after immunization (a drop was observed only 72 h after immunization). In old mice the titer of thymic serum factor virtually did not change after injection of sheep erythrocytes, while immunization of old mice preinjected with epithalamin significantly increased this parameter. Not only the values, but their dynamics in old mice injected with epithalamin corresponded to those in immunized adult animals.
PubMed ID
16224593 View in PubMed
Less detail

Anti-inflammatory effects of a cyclosporine receptor-binding compound, D-43787.

https://arctichealth.org/en/permalink/ahliterature13971
Source
J Pharmacol Exp Ther. 2002 May;301(2):738-46
Publication Type
Article
Date
May-2002
Author
Andreas Pahl
Meixia Zhang
Katalin Török
Hildegard Kuss
Ute Friedrich
Zoltan Magyar
Jozsef Szekely
Katalin Horvath
Kay Brune
Istvan Szelenyi
Author Affiliation
Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Erlangen, Germany.
Source
J Pharmacol Exp Ther. 2002 May;301(2):738-46
Date
May-2002
Language
English
Publication Type
Article
Keywords
Animals
Anti-Inflammatory Agents - pharmacology - therapeutic use
Arthritis, Experimental - drug therapy
Asthma - prevention & control
Cell Division - drug effects
Cyclophilin A - drug effects - metabolism
Cyclosporine - pharmacology
Cytokines - metabolism
Disease Models, Animal
Dose-Response Relationship, Drug
Guinea Pigs
Humans
Immunosuppressive Agents - pharmacology - therapeutic use
Indoles - chemistry - pharmacology - therapeutic use
Injections, Intraperitoneal
Injections, Subcutaneous
Leukocytes, Mononuclear - cytology - drug effects
Lysine - analogs & derivatives - chemistry - pharmacology - therapeutic use
Male
Peptidylprolyl Isomerase - metabolism
Rats
Rats, Inbred BN
Rats, Inbred Lew
Research Support, Non-U.S. Gov't
Th1 Cells - drug effects - metabolism
Th2 Cells - drug effects - metabolism
Abstract
By virtue of its binding to cyclophilin, the cellular receptor for cyclosporine (CsA), we could identify a new compound D-43787 [N-[(1-tert-butyloxycarbonyl)-indolin-2-(S)-carbonyl]-indolin-2-(S)-carbonacid-[N-epsilon-benzyloxycarbonyl)-2-(S)-lysin methylester]-amide] exhibiting immunomodulating properties. It inhibited cell proliferation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA)/ionomycin and anti-CD3/CD28 with an IC(50) of 0.3 microM. The protein phosphatase calcineurin, which is the target of the CsA-cyclophilin complex, is not inhibited by D-43787. It inhibited T helper cell (Th) 2 cytokines interleukin (IL)-4, -5, and -13 more effectively than the Th1 cytokine interferon (IFN)-gamma in human primary T cells. The IC(50) for IL-5 and IL-13 in TPA/ionomycin-stimulated peripheral blood mononuclear cells (PBMC) is 0.7 +/- 0.1 and 0.5 +/- 0.1 microM, respectively, whereas the IC(50) for IFN-gamma is 2.0 +/- 0.4 microM. When PBMC were stimulated with anti-CD3/CD28, the IC(50) for IL-4, -5, and -13 were 1.5 +/- 0.2, 1.8 +/- 0.2, and 1.9 +/- 0.4 microM, respectively. IFN-gamma was only partially inhibited under these conditions. This effect was even more pronounced in pure CD4(+) T cells. Pretreatment of human monocytes with D-43787 inhibited lipopolysaccharide-induced proinflammatory cytokines IL-6 and TNFalpha with an IC(50) of 1.2 +/- 0.1 and 4.7 +/- 0.9 microM, respectively. In vivo, D-43787 potently inhibited late-phase eosinophilia in actively sensitized and challenged guinea pigs (10 mg/kg, i.p.: 51%) and Brown-Norway rats (1 mg/kg, intrapulmonary: 66% 30 mg/kg, i.p.: 50%). In adjuvant-induced arthritis, D-43787 (10-40 mg/kg, b.i.d., i.p.) dose dependently reduced edema development on both hind paws. The potency of D-43787 was comparable with that of indomethacin and dexamethasone. In conclusion, we characterized a novel Th2 selective immunosuppressive drug with possible anti-asthmatic/anti-inflammatory effects. Its mode of action is distinct from that of CsA.
PubMed ID
11961080 View in PubMed
Less detail

ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion.

https://arctichealth.org/en/permalink/ahliterature127558
Source
Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):902-9
Publication Type
Article
Date
Apr-2012
Author
Jolanta M Siller-Matula
Yahye Merhi
Jean-François Tanguay
Daniel Duerschmied
Denisa D Wagner
Kathleen E McGinness
P Shannon Pendergrast
Jou-Ku Chung
Xianbin Tian
Robert G Schaub
Bernd Jilma
Author Affiliation
Department of Cardiology, Medical University of Vienna, Austria.
Source
Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):902-9
Date
Apr-2012
Language
English
Publication Type
Article
Keywords
Aged
Animals
Aptamers, Nucleotide - administration & dosage - pharmacokinetics - therapeutic use
Aptamers, Peptide - administration & dosage - pharmacokinetics - pharmacology
Austria
Biological Availability
Blood Platelets - drug effects - metabolism
Boston
Case-Control Studies
Collagen - metabolism
Cross-Sectional Studies
Dose-Response Relationship, Drug
Drug Stability
Female
Half-Life
Humans
Injections, Intravenous
Injections, Subcutaneous
Macaca fascicularis
Male
Middle Aged
Myocardial Infarction - blood
Platelet Activation - drug effects
Platelet Adhesiveness - drug effects
Platelet Aggregation Inhibitors - administration & dosage - pharmacokinetics - pharmacology
Platelet Function Tests
Protein Binding
Quebec
Rats
Swine
von Willebrand Factor - antagonists & inhibitors - metabolism
Abstract
We investigated the stability, pharmacokinetic, and pharmacodynamic profile of the 2(nd) generation anti-von Willeband factor aptamer ARC15105.
Platelet plug formation was measured by collagen/adenosine diphosphate-induced closure time with the platelet function analyzer-100 and platelet aggregation by multiple electrode aggregometry. Platelet adhesion was measured on denuded porcine aortas and in a flow chamber. Aptamer stability was assessed by incubation in nuclease rich human, monkey, and rat serum for up to 72 hours. Pharmacokinetic and pharmacodynamic profiles were tested in cynomolgus monkeys after IV and SC administration. The median IC(100) and IC(50) to prolong collagen/adenosine diphosphate-induced closure timewere 27 nmol/L and 12 nmol/L, respectively. ARC15105 (1.3 µmol/L) completely inhibited ristocetin-induced platelet aggregation in whole blood (P90% on denuded porcine aortas (P90% (P90% in blood samples taken 300 hours after a 20 mg/kg IV or SC dose in monkeys.
The potency, pharmacokinetic profile, and SC bioavailability of ARC15105 support its clinical investigation for chronic inhibition of von Willeband factor -mediated platelet activation.
PubMed ID
22282355 View in PubMed
Less detail

184 records – page 1 of 19.